Advanced search
Publication Cover
Cancer Biology & Therapy Volume 15, 2014 - Issue 12
Submit an article Journal homepage
1,638
Views
14
CrossRef citations to date
0
Altmetric
JOURNAL CLUB

Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer

William D Figg IITrinity College Dublin; University of Dublin; Dublin, IrelandCorrespondence[email protected]
,
Katherine CookLombardi Cancer Center; Georgetown University; Washington, DCUSA
&
Robert ClarkeLombardi Cancer Center; Georgetown University; Washington, DCUSA
Pages 1586-1587 | Received 09 Sep 2014, Accepted 28 Sep 2014, Published online: 23 Dec 2014

References

  • Seigel et al. Cancer Statistics, 2014. CA Cancer J Clin 2014; 64:9-29.
  • Rosen PR, Groshen S, Saigo PE, Kinne DW, Hillman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7:355-66; PMID:2918331
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365:1687-717; PMID:15894097; http://dx.doi.org/10.1016/S0140-6736(05)66544-0
  • Burstein HJ, Harris JR, Morrow M. Malignant Tumors of the Breast. In DeVita VT, Lawrence TS, Rosenberg SA eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011; 1401-1456.
  • Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-29; PMID:15545664; http://dx.doi.org/10.1200/JCO.2005.09.121
  • Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, et al. TEXT and SOFT Investigators. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18; PMID:24881463; http://dx.doi.org/10.1056/NEJMoa1404037
  • Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80:61-74; PMID:16815318; http://dx.doi.org/10.1016/j.clpt.2006.03.013
  • American Society of Clinical Oncology website http://am.asco.org/extending-adjuvant-tamoxifen-reduces-breast-cancer-recurrence-mortality.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.